Holen Sie sich die Stockscreener-App
64.02
3.56%
2.20
Handel nachbörslich:
64.02
Schlusskurs vom Vortag:
$61.82
Offen:
$62
24-Stunden-Volumen:
1.77M
Relative Volume:
0.74
Marktkapitalisierung:
$8.76B
Einnahmen:
$550.17M
Nettoeinkommen (Verlust:
$201.35M
KGV:
64.02
EPS:
1
Netto-Cashflow:
$232.07M
1W Leistung:
+10.13%
1M Leistung:
+6.35%
6M Leistung:
-16.85%
1J Leistung:
+79.93%
1-Tages-Spanne:
$61.88
$64.73
1-Wochen-Bereich:
$57.46
$66.80
52-Wochen-Spanne:
$34.34
$85.21
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Vergleichen Sie DOCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
64.02 | 11.58B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
279.18 | 45.01B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
69.63 | 11.53B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
89.27 | 8.04B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.35 | 6.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Blair William & Co. IL Sells 10,592 Shares of Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
DigitalOcean, Doximity, Freshworks, Braze, and Teradata Stocks Trade Up, What You Need To Know - Yahoo Finance
Doximity (NASDAQ:DOCS) Given New $59.00 Price Target at Canaccord Genuity Group - MarketBeat
191,798 Shares in Doximity, Inc. (NASDAQ:DOCS) Purchased by AGF Management Ltd. - MarketBeat
Doximity (NASDAQ:DOCS) Stock Price Expected to Rise, Raymond James Financial Analyst Says - MarketBeat
LPL Financial LLC Purchases 31,468 Shares of Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity buys AI clinical reference startup Pathway for $63 million - DOTmed
(08/13/25) DOCS: A Healthcare Play That’s on the Move After Beat-and-Raise - moneyshow.com
Doximity’s Earnings Call Highlights Growth and AI Advances - TipRanks
Doximity, Inc. (NYSE:DOCS) Q1 2026 Earnings Call Transcript - MSN
Doximity (NASDAQ:DOCS) Trading Down 6.5% on Insider Selling - MarketBeat
Doximity rises on Q1 beat; buys Canadian AI-based clinical reference firm - MSN
Jefferies Financial Group Inc. Sells 13,195 Shares of Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Insider Selling: Doximity, Inc. (NASDAQ:DOCS) Director Sells 5,000 Shares of Stock - MarketBeat
Doximity acquires AI-powered clinical decision support tool - TechTarget
Doximity (NASDAQ:DOCS) Price Target Raised to $69.00 at Piper Sandler - MarketBeat
Doximity Buying Pathway In $63 Million Deal - Pulse 2.0
DOCS Q2 Deep Dive: AI Investment, Product Expansion, and Broad-Based Customer Momentum - TradingView
What makes Doximity Inc. stock price move sharplyOversold Recovery Picks - thegnnews.com
Doximity, Inc. (NASDAQ:DOCS) Shares Acquired by Natixis Advisors LLC - MarketBeat
Analysts Weigh In on Green Thumb Industries, Doximity, and BioLife Solutions - AInvest
Doximity (DOCS) Soars 14% on Strong Earnings, Merger with AI-Powered Platform - MSN
Doximity Plummets 6.4%: What's Fueling the Selloff? - AInvest
Doximity (NASDAQ:DOCS) Announces Earnings Results - MarketBeat
Bank of Nova Scotia Makes New Investment in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity (DOCS) Is Up 14.2% After AI Acquisition and Revenue BeatWhat's Changed - simplywall.st
Sierra Summit Advisors LLC Makes New Investment in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity, Inc. (NASDAQ:DOCS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Doximity outlines 11% full-year revenue growth target as AI suite and Pathway acquisition accelerate platform expansion - MSN
Doximity (NASDAQ:DOCS) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Doximity (NASDAQ:DOCS) Price Target Raised to $75.00 at Needham & Company LLC - MarketBeat
Doximity First Quarter 2026 Earnings: Beats Expectations - Yahoo Finance
Doximity Shares Surge as Strategic Moves and Strong Earnings Impress Investors - timothysykes.com
10 Stocks with Eye-Popping Gains; 5 Jump to New Highs - Insider Monkey
Mackenzie Financial Corp Cuts Stock Holdings in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
U.S. Indexes Rose Friday; Doximity Topped Leaders - Barron's
Why Doximity's Recent Earnings and Guidance Signal a Buy Opportunity for Long-Term Growth - AInvest
Doximity stock price target raised to $69 by Piper Sandler on AI innovation - Investing.com South Africa
Why Is Doximity (DOCS) Stock Rocketing Higher Today - Yahoo Finance
DOCS Stock Surges: What’s Driving the Rise? - StocksToTrade
Doximity shares rise 11.78% intraday after acquiring Pathway Medical, a leader in AI clinical reference. - AInvest
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down - The Globe and Mail
Truist Securities Adjusts Price Target on Doximity to $62 From $61, Maintains Hold Rating - MarketScreener
Doximity Analysts Increase Their Forecasts After Strong Q1 Earnings - Benzinga
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday - Benzinga
Doximity (DOCS) Surges 11% Intraday: AI Acquisition Ignites Bullish Momentum Amid Record Revenue Growth - AInvest
Earnings call transcript: Doximity beats Q1 2026 expectations, stock surges - Investing.com India
Doximity Surges on Q1 Beat, Acquires Canadian AI Firm Pathway Medical - AInvest
Doximity stock rises on Q1 beat; AI acqusition (DOCS:NYSE) - Seeking Alpha
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.99%
2.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):